DePuy Synthes receives European CE Mark for new BI-MENTUMTM Dual Mobility System

Johnson & Johnson Medical Devices Companies today announces that DePuy Synthes, a leader in the cementless hip implant market, has obtained the European CE Mark on its new BI-MENTUMTM Dual Mobility System for use in patients with a higher risk of dislocation. BI-MENTUM features a standard femoral head articulating within a large polyethylene liner which then swivels within a metal shell. The system is designed to reduce the risk of dislocation, which can impact patient satisfaction and result in later revision costs.

More than three million hip arthroplasties have been registered in Europe since 1975. The incidence of instability caused by dislocation after Total Hip Arthroplasty (THA) in the primary and revision setting has been reported to be as high as 7% and 25%, respectively. Instability can have a significant impact on patients’ quality of life and mobility. In addition to the burden of repeat surgeries, dislocation can also impact costs in a resource-constrained environment. In fact, the surgical treatment of a dislocating THA can raise the cost of hip replacement by 342%.

With an increasing number of patients undergoing hip replacement surgery, surgeons need to address a broader range of surgical needs to help their patients stay active and get on with their lives. Securing the CE Mark on BI-MENTUM enables us to better serve our customers and patients across Europe with a solution that is designed to make a continued difference in hip replacement.”

Aaron Villaruz, Vice President and Global Platform Leader for Hips at DePuy Synthes

In 2018, DePuy Synthes announced a distribution agreement with SERF (Société d’Etude, de Recherche et de Fabrication), a French-based orthopedics company with a long and respected heritage in dual-mobility technology. DePuy Synthes is now bringing the latest dual-mobility acetabular cups, identical to Serf® dual-mobility cups, under its own brand name, BI-MENTUM Dual Mobility. This clinically proven dual-mobility technology has achieved a track record of 100% cup survivorship at 10 years and also an implant milestone of 165,000 cups since 2007.

BI-MENTUM, currently available in the United States, is scheduled to be available in select European markets in April 2020. This dual-mobility system integrates seamlessly with all DePuy Synthes hip stems with highly polished necks, including the market-leading CORAIL® Hip System with more than 2.5 million implantations to date. Sharing in the French design legacy, CORAIL is backed by registries of peer-reviewed clinical evidence documenting more than 350,000 CORAIL® implantations with a 93.7% survivorship rate at 30 years.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    DePuy Synthes. (2022, September 06). DePuy Synthes receives European CE Mark for new BI-MENTUMTM Dual Mobility System. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20200312/DePuy-Synthes-receives-European-CE-Mark-for-new-BI-MENTUMTM-Dual-Mobility-System.aspx.

  • MLA

    DePuy Synthes. "DePuy Synthes receives European CE Mark for new BI-MENTUMTM Dual Mobility System". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20200312/DePuy-Synthes-receives-European-CE-Mark-for-new-BI-MENTUMTM-Dual-Mobility-System.aspx>.

  • Chicago

    DePuy Synthes. "DePuy Synthes receives European CE Mark for new BI-MENTUMTM Dual Mobility System". News-Medical. https://www.news-medical.net/news/20200312/DePuy-Synthes-receives-European-CE-Mark-for-new-BI-MENTUMTM-Dual-Mobility-System.aspx. (accessed November 22, 2024).

  • Harvard

    DePuy Synthes. 2022. DePuy Synthes receives European CE Mark for new BI-MENTUMTM Dual Mobility System. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20200312/DePuy-Synthes-receives-European-CE-Mark-for-new-BI-MENTUMTM-Dual-Mobility-System.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
DePuy Synthes launches the SYMPHONY Occipito-Cervico-Thoracic System